This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given to patients with different types of cancer to see if it shrinks their tumors.
1 Primary · 3 Secondary · Reporting Duration: 6 months after dose administration for each dosed subject.
24 Total Participants · 1 Treatment Group
Primary Treatment: CRX100 suspension for infusion · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: